^
    Back
    Association details:
    Biomarker:MMP17 expression + EGFR expression + RB1 expression
    Cancer:Triple Negative Breast Cancer
    Drug:erlotinib (EGFR inhibitor) +
    Ibrance (palbociclib) (CDK4 inhibitor, CDK6 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Clin Cancer Res
    Title:

    Expression of MT4-MMP, EGFR, and RB in Triple-Negative Breast Cancer Strongly Sensitizes Tumors to Erlotinib and Palbociclib Combination Therapy

    Published date:
    03/15/2019
    Excerpt:
    Both TNBC xenografts and PDX expressing MT4-MMP, EGFR, and RB, but not PDX-TNBC with RB loss, were sensitive to erlotinib and palbociclib with an additive effect of combination therapy. Moreover, this combination was efficient in another PDX-TNBC expressing the three biomarkers and resistant to erlotinib alone.
    DOI:
    10.1158/1078-0432.CCR-18-1880